Sridevi Devaraj1, Uma Singh, Ishwarlal Jialal. 1. Laboratory for Atherosclerosis and Metabolic Research, University of California Davis Medical Center, Sacramento, California, and VA Medical Center, Mather, USA.
Abstract
PURPOSE OF REVIEW: Low-grade inflammation is characteristic of the metabolic syndrome (MetS). C-reactive protein (CRP), the best characterized biomarker of inflammation, is also an independent predictor of future cardiovascular events. The purpose of this review is to outline the role of inflammation and high sensitivity CRP in the MetS. RECENT FINDINGS: Emerging laboratory and epidemiological data now link inflammation and high sensitivity CRP to insulin resistance and adiposity and other features of MetS. Furthermore, in large prospective studies, increased high sensitivity CRP levels in MetS confer greater cardiovascular risk. CRP has been shown to impair insulin signaling and contributes to atherothrombosis. SUMMARY: Thus, although a high CRP level predisposes to increased cardiovascular risk in MetS, future investigation is warranted on the in-vivo role of CRP in mediating vascular effects and resulting in increased cardiovascular events in MetS patients.
PURPOSE OF REVIEW: Low-grade inflammation is characteristic of the metabolic syndrome (MetS). C-reactive protein (CRP), the best characterized biomarker of inflammation, is also an independent predictor of future cardiovascular events. The purpose of this review is to outline the role of inflammation and high sensitivity CRP in the MetS. RECENT FINDINGS: Emerging laboratory and epidemiological data now link inflammation and high sensitivity CRP to insulin resistance and adiposity and other features of MetS. Furthermore, in large prospective studies, increased high sensitivity CRP levels in MetS confer greater cardiovascular risk. CRP has been shown to impair insulin signaling and contributes to atherothrombosis. SUMMARY: Thus, although a high CRP level predisposes to increased cardiovascular risk in MetS, future investigation is warranted on the in-vivo role of CRP in mediating vascular effects and resulting in increased cardiovascular events in MetS patients.
Authors: John D Vu; Jack B Vu; Jose R Pio; Shaista Malik; Stanley S Franklin; Roland S Chen; Nathan D Wong Journal: Am J Cardiol Date: 2005-09-01 Impact factor: 2.778
Authors: J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto Journal: JAMA Date: 1998-05-27 Impact factor: 56.272
Authors: Jing Li; Andreas J Flammer; Ryan J Lennon; Rebecca E Nelson; Rajiv Gulati; Paul A Friedman; Randal J Thomas; Nicole P Sandhu; Qi Hua; Lilach O Lerman; Amir Lerman Journal: Mayo Clin Proc Date: 2012-09-12 Impact factor: 7.616
Authors: Mark M Smits; Pier Woudstra; Kristina M Utzschneider; Jenny Tong; Fernando Gerchman; Mirjam Faulenbach; Darcy B Carr; Kathryn Aston-Mourney; Alan Chait; Robert H Knopp; James B Meigs; Edward J Boyko; Steven E Kahn Journal: Ann Epidemiol Date: 2013-03-25 Impact factor: 3.797